RS51135B - Formulacija suspenzije feksofenadina - Google Patents
Formulacija suspenzije feksofenadinaInfo
- Publication number
- RS51135B RS51135B RSP-2009/0360A RSP20090360A RS51135B RS 51135 B RS51135 B RS 51135B RS P20090360 A RSP20090360 A RS P20090360A RS 51135 B RS51135 B RS 51135B
- Authority
- RS
- Serbia
- Prior art keywords
- sorbitol
- fexofenadine
- propylparaben
- solution
- sucrose
- Prior art date
Links
- 229960003592 fexofenadine Drugs 0.000 title abstract 3
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000000725 suspension Substances 0.000 title 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 abstract 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 abstract 4
- 239000000600 sorbitol Substances 0.000 abstract 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract 3
- 229930006000 Sucrose Natural products 0.000 abstract 3
- 239000005720 sucrose Substances 0.000 abstract 3
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 abstract 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 abstract 2
- -1 fexofenadine dihydrate Chemical class 0.000 abstract 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 abstract 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 abstract 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 abstract 2
- 239000000243 solution Substances 0.000 abstract 2
- 239000000811 xylitol Substances 0.000 abstract 2
- 235000010447 xylitol Nutrition 0.000 abstract 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 abstract 2
- 229960002675 xylitol Drugs 0.000 abstract 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 abstract 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 abstract 1
- 239000007853 buffer solution Substances 0.000 abstract 1
- 229940067596 butylparaben Drugs 0.000 abstract 1
- 239000000416 hydrocolloid Substances 0.000 abstract 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000007971 pharmaceutical suspension Substances 0.000 abstract 1
- TUMYXYVXTFDMTJ-UHFFFAOYSA-M potassium;4-propoxycarbonylphenolate Chemical compound [K+].CCCOC(=O)C1=CC=C([O-])C=C1 TUMYXYVXTFDMTJ-UHFFFAOYSA-M 0.000 abstract 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 abstract 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 abstract 1
- 229960003415 propylparaben Drugs 0.000 abstract 1
- OGBHACNFHJJTQT-UHFFFAOYSA-M sodium;4-butoxycarbonylphenolate Chemical compound [Na+].CCCCOC(=O)C1=CC=C([O-])C=C1 OGBHACNFHJJTQT-UHFFFAOYSA-M 0.000 abstract 1
- IXMINYBUNCWGER-UHFFFAOYSA-M sodium;4-propoxycarbonylphenolate Chemical compound [Na+].CCCOC(=O)C1=CC=C([O-])C=C1 IXMINYBUNCWGER-UHFFFAOYSA-M 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
- 239000000080 wetting agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Saccharide Compounds (AREA)
Abstract
Farmaceutska suspenzija u vodi, koja ima pH od oko 4,25 do oko 9,43, podešen sa nekim puferskim sistemom, naznačena time, što sadrži, iskazano kao masa/zapremina (g/10 mL),oko 0,03% do oko 4,80% Oblika I cviterjona feksofenadin dihidrata formule (I), koji ima veličinu čestica manju od oko 280 pm za najmanje oko 90% Oblika I cviterjona feksofenadin dihidrata;oko 0,01% do oko 0,20% agensa za kvašenje;agens za suspendovanje, koji se bira između oko 0,10% do oko 0,50% hidrokoloidnegume, ili od oko 0,1% do oko 1,0% hidroksietilceluloze;sistem zaslađivača, koji se sastoji odoko 5% do oko 40% saharoze ili invertovane saharoze; i0% do oko 40% ksilitola, sorbitola ili rastvora sorbitola, ili rastvora maltitola;pod uslovom da je odnos količina (saharoza ili invertovana saharoza) : (ksilitol, sorbitol,ili rastvor sorbitola, ili rastvor maltitola) jednak ili veći od oko 1:1; isistem prezervativa, koji se sastoji odoko 0,010% do oko 0,058% propilparabena, natrijum-propilparabena ili kalijum-propilparabena; ioko 0,0005% do oko 0,0350% butilparabena ili natrijum-butilparabena.Prijava sadrži još 92 patentna zahteva.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75030305P | 2005-12-14 | 2005-12-14 | |
| PCT/US2006/047393 WO2007070517A2 (en) | 2005-12-14 | 2006-12-12 | Fexofenadine suspension formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS51135B true RS51135B (sr) | 2010-10-31 |
Family
ID=38120312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RSP-2009/0360A RS51135B (sr) | 2005-12-14 | 2006-12-12 | Formulacija suspenzije feksofenadina |
Country Status (39)
| Country | Link |
|---|---|
| US (1) | US8933097B2 (sr) |
| EP (1) | EP1965768B1 (sr) |
| JP (1) | JP5308824B2 (sr) |
| KR (1) | KR101452792B1 (sr) |
| CN (1) | CN101316580B (sr) |
| AR (1) | AR058323A1 (sr) |
| AT (1) | ATE431137T1 (sr) |
| AU (1) | AU2006326551B2 (sr) |
| BR (1) | BRPI0619895B1 (sr) |
| CA (1) | CA2633086C (sr) |
| CR (1) | CR9993A (sr) |
| CY (1) | CY1109320T1 (sr) |
| DE (1) | DE602006006870D1 (sr) |
| DK (1) | DK1965768T3 (sr) |
| DO (1) | DOP2006000274A (sr) |
| EC (1) | ECSP088532A (sr) |
| EG (1) | EG25866A (sr) |
| ES (1) | ES2327168T3 (sr) |
| HK (1) | HK1123197A1 (sr) |
| HN (1) | HN2008000875A (sr) |
| HR (1) | HRP20090411T1 (sr) |
| IL (1) | IL192067A (sr) |
| JO (1) | JO2549B1 (sr) |
| MA (1) | MA30152B1 (sr) |
| MY (1) | MY146988A (sr) |
| NO (1) | NO339877B1 (sr) |
| NZ (1) | NZ568943A (sr) |
| PE (1) | PE20071003A1 (sr) |
| PL (1) | PL1965768T3 (sr) |
| PT (1) | PT1965768E (sr) |
| RS (1) | RS51135B (sr) |
| RU (1) | RU2405538C2 (sr) |
| SI (1) | SI1965768T1 (sr) |
| TN (1) | TNSN08186A1 (sr) |
| TW (1) | TWI377061B (sr) |
| UA (1) | UA89584C2 (sr) |
| UY (1) | UY30021A1 (sr) |
| WO (1) | WO2007070517A2 (sr) |
| ZA (1) | ZA200803985B (sr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101546774B1 (ko) | 2008-07-29 | 2015-08-24 | 엘지전자 주식회사 | 휴대 단말기 및 그 동작제어 방법 |
| CN103957894A (zh) | 2011-10-19 | 2014-07-30 | R.P.谢勒技术有限公司 | 两相药物递送系统 |
| TW201542240A (zh) * | 2013-07-01 | 2015-11-16 | Aventis Pharma Inc | 包含菲索芬那定（ｆｅｘｏｆｅｎａｄｉｎｅ）之口服液態醫藥組合物 |
| BR112015032791A2 (pt) * | 2013-07-03 | 2017-07-25 | Scherer Technologies Llc R P | composição para uso como enchimento de cápsula, e, cápsula |
| CN103610645B (zh) * | 2013-11-25 | 2016-05-11 | 浙江万晟药业有限公司 | 一种非索非那定盐酸盐的药物组合物及制备方法 |
| CN106806346B (zh) * | 2015-12-01 | 2020-09-11 | 国药集团广东环球制药有限公司 | 一种非索非那定盐酸盐干混悬剂制剂及其制备方法 |
| US11207307B2 (en) * | 2016-06-16 | 2021-12-28 | Azurity Pharmaceuticals, Inc. | Composition and method for proton pump inhibitor suspension |
| US11318095B2 (en) | 2017-06-02 | 2022-05-03 | Teika Pharmaceutical Co., Ltd. | Micelle for solubilizing a sparingly water-soluble ingredient and solution comprising the same |
| US11633478B2 (en) | 2019-07-16 | 2023-04-25 | Azurity Pharmaceuticals, Inc. | Compositions and kits for Omeprazole suspension |
| US10751333B1 (en) | 2019-07-16 | 2020-08-25 | Cutispharma, Inc. | Compositions and kits for omeprazole suspension |
| WO2022175829A1 (en) | 2021-02-17 | 2022-08-25 | Cellix Bio Private Limited | Topical formulations and compositions |
| CN115715759B (zh) * | 2022-11-03 | 2024-01-12 | 京海盛达(北京)科技有限公司 | 一种抗组胺混悬剂及其制备方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4254129A (en) | 1979-04-10 | 1981-03-03 | Richardson-Merrell Inc. | Piperidine derivatives |
| US4829064A (en) | 1987-06-08 | 1989-05-09 | Analgesic Associates | Cough/cold mixtures comprising non-sedating antihistamine drugs |
| CA2189007C (en) | 1994-05-18 | 2004-03-02 | Daniel R. Henton | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudormophs thereof |
| US6132758A (en) | 1998-06-01 | 2000-10-17 | Schering Corporation | Stabilized antihistamine syrup |
| US6319513B1 (en) * | 1998-08-24 | 2001-11-20 | The Procter & Gamble Company | Oral liquid mucoadhesive compounds |
| GB9822170D0 (en) | 1998-10-13 | 1998-12-02 | Danbioyst Uk Ltd | Novel formulations of fexofenadine |
| US20060083691A1 (en) * | 2000-05-10 | 2006-04-20 | Wermeling Daniel P | Intranasal opioid compositions, delivery devices and methods of using same |
| US20040248935A1 (en) | 2001-07-31 | 2004-12-09 | Milla Frederico Junquera | Fexofenadine polymorph |
| US6723348B2 (en) * | 2001-11-16 | 2004-04-20 | Ethypharm | Orodispersible tablets containing fexofenadine |
| MXPA05008193A (es) | 2003-01-30 | 2006-05-25 | Ethypharm Sa | Particulas con revestimiento que oculta el sabor, proceso para la preparacion de las mismas y tabletas orodispersables que contienen dichas particulas revestidas. |
| US20050250737A1 (en) * | 2003-11-12 | 2005-11-10 | Allergan, Inc. | Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods |
| US20050266031A1 (en) | 2004-05-25 | 2005-12-01 | Jay Dickerson | Pharmaceutical suspension composition |
| PL2522365T3 (pl) * | 2004-11-24 | 2017-05-31 | Meda Pharmaceuticals Inc. | Kompozycje zawierające azelastynę i sposoby ich zastosowania |
| AU2006278874A1 (en) | 2005-07-27 | 2007-02-15 | Sandoz Ag | A process for the preparation of substituted phenyl ether compounds and rosiglitazone |
| WO2007017905A1 (en) * | 2005-08-05 | 2007-02-15 | Lupin Limited | Oral pharmaceutical suspension compositions of fexofenadine |
-
2006
- 2006-12-06 DO DO2006000274A patent/DOP2006000274A/es unknown
- 2006-12-12 JP JP2008545740A patent/JP5308824B2/ja not_active Expired - Fee Related
- 2006-12-12 DK DK06839331T patent/DK1965768T3/da active
- 2006-12-12 CN CN200680044516XA patent/CN101316580B/zh active Active
- 2006-12-12 RS RSP-2009/0360A patent/RS51135B/sr unknown
- 2006-12-12 SI SI200630374T patent/SI1965768T1/sl unknown
- 2006-12-12 EP EP06839331A patent/EP1965768B1/en active Active
- 2006-12-12 RU RU2008128418/15A patent/RU2405538C2/ru not_active IP Right Cessation
- 2006-12-12 BR BRPI0619895-3A patent/BRPI0619895B1/pt active IP Right Grant
- 2006-12-12 PT PT06839331T patent/PT1965768E/pt unknown
- 2006-12-12 AT AT06839331T patent/ATE431137T1/de active
- 2006-12-12 WO PCT/US2006/047393 patent/WO2007070517A2/en active Application Filing
- 2006-12-12 AR ARP060105470A patent/AR058323A1/es not_active Application Discontinuation
- 2006-12-12 PL PL06839331T patent/PL1965768T3/pl unknown
- 2006-12-12 UA UAA200809121A patent/UA89584C2/uk unknown
- 2006-12-12 DE DE602006006870T patent/DE602006006870D1/de active Active
- 2006-12-12 AU AU2006326551A patent/AU2006326551B2/en active Active
- 2006-12-12 NZ NZ568943A patent/NZ568943A/en not_active IP Right Cessation
- 2006-12-12 ES ES06839331T patent/ES2327168T3/es active Active
- 2006-12-12 CA CA2633086A patent/CA2633086C/en active Active
- 2006-12-12 KR KR1020087014471A patent/KR101452792B1/ko active IP Right Grant
- 2006-12-12 MY MYPI20081743A patent/MY146988A/en unknown
- 2006-12-12 PE PE2006001593A patent/PE20071003A1/es not_active Application Discontinuation
- 2006-12-14 JO JO2006458A patent/JO2549B1/en active
- 2006-12-14 TW TW095146788A patent/TWI377061B/zh not_active IP Right Cessation
- 2006-12-15 UY UY30021A patent/UY30021A1/es not_active Application Discontinuation
-
2008
- 2008-04-24 TN TNP2008000186A patent/TNSN08186A1/en unknown
- 2008-05-06 ZA ZA200803985A patent/ZA200803985B/xx unknown
- 2008-05-20 CR CR9993A patent/CR9993A/es not_active Application Discontinuation
- 2008-06-11 IL IL192067A patent/IL192067A/en not_active IP Right Cessation
- 2008-06-12 EC EC2008008532A patent/ECSP088532A/es unknown
- 2008-06-13 HN HN2008000875A patent/HN2008000875A/es unknown
- 2008-06-13 US US12/138,468 patent/US8933097B2/en active Active
- 2008-06-15 EG EG2008060996A patent/EG25866A/xx active
- 2008-06-26 NO NO20082904A patent/NO339877B1/no not_active IP Right Cessation
- 2008-07-11 MA MA31103A patent/MA30152B1/fr unknown
-
2009
- 2009-01-23 HK HK09100732.4A patent/HK1123197A1/xx not_active IP Right Cessation
- 2009-07-23 HR HR20090411T patent/HRP20090411T1/hr unknown
- 2009-08-12 CY CY20091100862T patent/CY1109320T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RS51135B (sr) | Formulacija suspenzije feksofenadina | |
| WO2008133330A1 (ja) | ４，５－エポキシモルヒナン誘導体を含有する安定な固形製剤 | |
| JP2009519935A5 (sr) | ||
| JP2018523635A5 (sr) | ||
| HRP20200255T1 (hr) | Formulacija ac220 osušena raspršivačem | |
| HRP20150770T1 (hr) | Terapijska kombinacija koja sadrži dolutegravir, abakavir i lamivudin | |
| CA2341568A1 (en) | Stabilized pharmaceutical composition in lyophilized form | |
| MX2009011619A (es) | Formulaciones que contienen clopidogrel y eter sulfoalquilico-ciclodextrina y metodos de uso. | |
| RU2001108569A (ru) | Стабилизированная фармацевтическая композиция в лиофилизированной форме | |
| RU2017134002A (ru) | Стабильные композиции тетрагидробиоптерина | |
| EA201400679A1 (ru) | Композиция сухого порошка производного азола для ингаляции | |
| HRP20070322T3 (en) | Pellets containing venlafaxine hydrochloride | |
| HRP20180774T1 (hr) | Orodisperzibilni dezmopresin za povećanje početnog razdoblja sna neometanog s nokturijom | |
| CY1112917T1 (el) | Υγρες στοματικες συνθεσεις | |
| HRP20192213T1 (hr) | Farmaceutski pripravak koji sadrži mirabegron | |
| HRP20160802T1 (hr) | Čvrsti farmaceutski pripravci koji sadrže derivate biopterina i upotreba takvih pripravaka | |
| HRP20221381T1 (hr) | C-manozidni spojevi korisni za liječenje infekcija urinarnog trakta | |
| SE9903831D0 (sv) | Formulation of substituted benzimidazoles | |
| JPS63215622A (ja) | 経口投与用医薬組成物 | |
| HRP20161594T1 (hr) | Pripravci za liječenje rozaceje koji sadrže kitozan i amid dikarboksilne kiseline | |
| JP2011516544A5 (sr) | ||
| JP2020510619A5 (sr) | ||
| HRP20200196T1 (hr) | Fiziološki balansirane injektabilne formulacije fosnetupitanta | |
| DK1102594T3 (da) | Anvendelse af natriumchlorid til nedsættelse af den gastrointestinale toxicitet af derivater af camptothecin | |
| WO2009008004A3 (en) | Sustained release formulations of divalproex sodium |